09:47 AM EST - Amorfix Life Sciences Ltd. : reported a narrower fourth-quarter net loss from operations of $1.25 million compared with $1.38 million for the three months ended March 31, 2009. However, net loss per share from operations stood flat at $0.03. The company recorded service revenue from the A(4) test and also recorded revenue related to a third party research agreement totaling $45,516. General and administrative expenses for the three months ended March 31, 2010 were $347,867 which is comparable to the costs of $323,108 that were incurred in the corresponding period in 2009. Amorfix Life Sciences Ltd.
shares T.AMF are trading even at $0.25.
